Subscribe
shutterstock_1492764635_michael_vi
Michael Vi / Shutterstock.com
4 February 2021Big PharmaAlex Baldwin

Coherus secures toripalimab rights for US and Canada

Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.

More on this story

Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB